Halted in US by FDA hold, Bellicum buoyed by some positive numbers from its European T cell study for pediatric AML
Shares of Bellicum Pharmaceuticals $BLCM got a badly needed boost this morning as the biotech — put in at least temporary limbo by an FDA hold …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
